search button

CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia

  • Authors:
    • Mohammed T. Tayeb
    • Caroline Clark
    • Linda Sharp
    • Neva E. Haites
    • Patrick H. Rooney
    • Graeme I. Murray
    • Simon N.L. Payne
    • Howard L. McLeod

  • View Affiliations

  • Published online on: May 1, 2002     https://doi.org/10.3892/or.9.3.653
  • Pages: 653-655
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PRCa) is one of the most common causes of cancer death in men and determinants of PRCa risk remain largely unidentified. Benign prostatic hyperplasia (BPH) is found in the majority of ageing men and has been linked with PRCa. CYP3A4 may influence PRCa through its role in testosterone metabolism. This nested case-control study assessed a CYP3A4 single nucleotide polymorphism as a risk factor for developing PRCa in patients with BPH. The CYP3A4 variant allele identified men with BPH who are at increased risk of progressing to PRCa (odds ratio 6.3, 95% CI 2.3-17.3), providing a potential tool to assist prediction strategies for this disease.

Related Articles

Journal Cover

May-June 2002
Volume 9 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.8
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 8.5
  • CiteScore Rank: Q1: #74/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.719
  • SCImago Journal Rank (SJR): 0.864
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI, Payne SN and McLeod HL: CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 9: 653-655, 2002.
APA
Tayeb, M.T., Clark, C., Sharp, L., Haites, N.E., Rooney, P.H., Murray, G.I. ... McLeod, H.L. (2002). CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncology Reports, 9, 653-655. https://doi.org/10.3892/or.9.3.653
MLA
Tayeb, M. T., Clark, C., Sharp, L., Haites, N. E., Rooney, P. H., Murray, G. I., Payne, S. N., McLeod, H. L."CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia". Oncology Reports 9.3 (2002): 653-655.
Chicago
Tayeb, M. T., Clark, C., Sharp, L., Haites, N. E., Rooney, P. H., Murray, G. I., Payne, S. N., McLeod, H. L."CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia". Oncology Reports 9, no. 3 (2002): 653-655. https://doi.org/10.3892/or.9.3.653